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Individual Relationship Between Progression of 
Radiological Damage and the Acute Phase 
Response in Early Rheumatoid Arthritis. Towards 
Development of a Decision Support System
MIEK A. van LEEUWEN, MARTIN H. van RIJSWIJK, WIM J. SLUITER, PIET L.C.M. van RIEL, INA H. KUPER, 
LEVINUS B.A. van de PUTTE, MARK B. PEPYS, and PIETER C. LIMBURG
A B ST R A C T  Objective. Evaluation of the individual relationship between C-reactive protein (CRP) production or
erythrocyte sedimentation rate (ESR) and progression of radiologic damage in early rheumatoid 
arthritis (RA), to improve the predictive value of monitoring the acute phase response.
Methods. The relationship was modeled mathematically using adjustments for discontinuity in the 
radiographic scoring system and for clustering in the occurrence of score points in the initial phase.
The model was evaluated in a prospective study of 149 patients with early RA, monthly CRP assays, 
and 6-monthly Sharp scores of radiographs of the hands and feet.
Results. Time integrated CRP values correlated closely with radiologic progression in each patient, 
but th,ere was considerable variation between individuals with similar radiographic scores. The the­
oretical model accommodated these results, and based on CRP measurements and radiographic 
scores over 6 months, it provided a k value for each patient that reflected the individual relationship 
between CRP and radiologic damage. Using this k value combined with actual CRP levels over 3 
and 6 years, the model accurately predicted the extent of radiologic progression that was actually 
observed at these times. Best results were obtained using estimation of the k value from 6 or 12 
month observational data. The model has been incorporated into a software program for routine clin­
ical use that indicates the levels to which CRP should fall to prevent further joint damage. Similar 
results were obtained for ESR,
Conclusion. A model has been established defining the individual relationship between time inte­
grated CRP and ESR values, reflecting rheumatoid disease activity, and progression of radiologic 
damage. It accurately predicts outcome from 6 months after presentation and can be used as a prac­
tical decision support system. (J Rheumatol 1997;24:20-27)
Key Indexing Terms:
RHEUMATOID ARTHRITIS 
RADIOLOGICAL PROGRESSION
The recent trend to start aggressive therapy early in rheuma­
toid arthritis (RA) is based on increasing evidence that irre­
versible joint destruction may start during the first months
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ACUTE PHASE RESPONSE 
C-REACTIVE PROTEIN
of the disease, and that early changes in the small joints are 
predictive of future disability, including damage in large 
joints1-4. Radiological assessment of progressive arthropa­
thy in RA is a direct and objective measure of outcome. It 
reflects the results of chronic arthritis, including enzymatic 
degradation of cartilage and erosion of bone, that are essen­
tially irreversible5,6. Radiological damage thus represents 
the cumulative effects of the disease during the preceding 
period, but is independent of current disease activity.
There are several objective markers that identify patients 
with RA at risk of a progressive course and poor outcome7. 
Since treatment that modifies the rheumatoid process may 
alter the outcome, it is important to determine which of the 
variables associated with activity reflect most closely those 
aspects of the disease responsible for a particular measure of 
outcome. Transformation of serially measured process vari­
ables into time integrated values, by calculating the area 
under the curve (AUC), is very useful for this purpose and 
permits comparison with outcome measures, such as radio­
logical damage, that are cumulative.
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The acute phase response, measured directly by determi­
nation of the serum C-reactive protein (CRP) concentration 
or indirectly by the erythrocyte sedimentation rate (ESR), is 
a sensitive objective indicator of both the activity and the 
extent of synovial inflammation8,9, and several studies have 
shown that persistent reduction of ESR and CRP values is 
accompanied by reduced progression of radiological dam­
age10,11. We have reported a highly significant correlation 
between time integrated values of ESR and CRP and radio­
logical progression in a large cohort of patients with RA dur­
ing the first 3 years of the disease12. However, there was 
wide variation between individuals in the absolute values of 
CRP or ESR corresponding to particular levels of disease 
activity and joint damage. This limits the use of acute phase 
reactants as indicators of radiological progression in clinical 
practice since time integrated values cannot be translated 
directly into radiologic scores in the individual patient. We 
evaluated these interindividual differences and developed a 
model to describe the individual relationship between CRP 
and radiological progression during the first years of the dis­
ease.
MATERIALS AND METHODS
All patients attending our clinics with classical or definite RA according to 
the 1958 American Rheumatology Association (ARA) criteria, with joint 
symptoms compatible with arthritis for less than one year, and who had not 
previously received disease modifying antirheumatic drugs (DMARD), 
were invited to participate in a prospective study. All patients met these 
inclusion criteria at study entry. Retrospectively 146 of the 149 patients 
also fulfilled the 1987 ARA criteria. We analyzed data from 149 patients 
who had completed 3 years of followup, and from a subgroup of the first 
54 of the 149 patients who completed 6 years of followup. At monthly vis­
its during the first 3 years, and at 3-monthly visits thereafter, clinical and 
laboratory measurements were performed, including CRP levels by 
ELISA13. IgM rheumatoid factor (RF) was measured by ELISA14 at study 
entry. The sera of all 149 patients were typed for HLA-DR locus. 
Radiographs of hands and feet were obtained every 6 months during the 
first 3 years (N = 149). In the subgroup of 54 patients who completed 6 
years of followup, radiographs were obtained after 6 years as well. Joint 
damage in the hands and feet was assessed by Sharp’s method15 with some 
modifications, in particular inclusion of the foot joints, as described by van 
der Heijde, et a /16. Radiographs were assessed in chronological order per 
patient by 2 observers. The interobserver variation was assessed in 120 
pairs of radiographs and yielded a correlation of > 0.90 for the total scores. 
Erosions were counted in 56 joints/joint areas, with a maximum erosion 
score of 5/joint/joint area: 10 metacarpophalangeal (MCP) joints, 8 proxi­
mal interphalangeal (PIP) joints, 2 interphalangeal (IP) joints of the 
thumbs, left (L) and right (R) first metacarpal bone, L and R radius and 
ulnar bone, L and R trapezium+trapezoid (as one unit), L and R navicular 
bone, L and R lunate bone, 2 IP joints of the big toes, and 10 metatar­
sophalangeal (MTP) joints. The maximum erosion score in these 12 foot 
joints was 10/joint: 5 points for the proximal side and 5 points for the dis­
tal side of the joints. Therefore, 24 foot joint areas were assessed for ero­
sions with a maximum of 5 points/area. Joint space narrowing was assessed 
in 42 joints, graded from 0 to 4/joint: 10 MCP joints, 8 PIP joints, L and R 
3rd, 4th and 5th carpometacarpal joints, L and R multangular-navicular 
joints, L and R capitate-navicular-lunate joints, L and R radiocarpal joints,
10 MTP joints, and 2 IP joints of the big toes. The maximum numbers of 
erosions in the hands and feet are 160 and 120, and the maximum scores 
for joint space narrowing are 120 and 48, respectively, giving a maximum 
total score (X score) of 448. The progression of radiological damage over
a time period (Ô-X score) was determined by subtracting the initial score 
from the final score. During the first 3 years, the monthly CRP levels were 
transformed into time integrated values by plotting CRP levels against time 
(weeks) and calculating the AUC for each monthly interval by means of the 
trapezoidal rule. Cumulative AUC values were calculated for each 6 month 
period (8-CRPAUC) between consecutive radiographic studies by summa­
tion of the monthly AUC values. For the period from 3 to 6 years of fol­
lowup, time integrated CRP values were calculated similarly using 3- 
monthly CRP levels.
Patients were treated with nonsteroidal antiinflammatory drugs 
(NSAID) and DMARD as clinically indicated, with hydroxychloroquine or 
sulfasalazine as the first choice among DMARD, followed in order by 
intramuscular gold, D-penicillamine, azathioprine, and methotrexate. Low 
dose corticosteroids were allowed as adjuvant therapy.
Theoretical model. A theoretical mathematical model was developed to 
describe the relationship between quantitative assessment of progression of 
radiological damage, represented by the X score, and cumulative disease 
activity, represented by time integrated CRP values. This model comprises 
the following variables: (I) the number of joints (n) included in the scoring 
system, (2) the maximum possible radiologic score per joint (m) (resulting 
in a total maximum score of N), (3) the observed score per joint (p), (4) the 
cumulative disease activity over time CRP AUC, and (5) the individual 
relationship between disease activity and joint damage in each patient is 
represented by a constant (k),
Assuming a proportional relationship between the rate of progression of 
radiological damage on the one hand, and disease activity (CRP level) and 
the residual joint area still available for damage (m~p) on the other hand, 
then the rate of progression/joint can be expressed as k*CRP(m-p), 
Assuming further that joint scores develop randomly, then the relationship 
between radiological damage (sum of observed p values) and cumulative 
disease activity can be expressed in the equation:
radiological damage = N*(l-e~k‘CR|1AUC) ( 1)
The value of k is assumed to be constant in each individual patient, but 
may show considerable variation between patients. The product k*CRP 
AUC thus corresponds to the cumulative effect of disease, or “disease 
dose,” in each individual. The relationship between k-CRP AUC and radio­
logical damage is shown in Figure 1 (curve a), using N = 448 according to 
the scoring system.
Fitting the model to the actual assessment of radiologic scores will 
improve when the following points are taken into consideration:
Discrete character o f the score. Unlike radiological damage, which is basi­
cally a continuous process, a radiologic scoring system like Sharp’s method 
produces a discrete variable (score), expressed by integers. As the disease 
advances, the scores per joint at any given time will be randomly distrib­
uted between “just received a score point” and “about to receive a score 
point,” and therefore the radiologic scores estimated by the model will lag 
behind the radiological damage with a mean of 0.5 for each joint. This is 
accommodated in equation 2:
radiologic score = N*(l-e_k'CRPAUC), — 0.5n (2)
in which n = 98 (56 for erosions + 42 for narrowing; domain restricted to 
results > 0). The curve expressed by this formula is shown in Figure 1, 
curve b.
Synchronous occurrence o f scoring points. In the initial phase of disease, 
score points tend to be more or less synchronized. Theoretically, at the 
starting point of the disease (a time point we do not know exactly), no joint 
is damaged yet, and all joints are perfectly synchronized at exactly 1.0 
score point away from their first score. Therefore, in the very early stages 
of the disease, it may be expected that several joints will reach their first 
score at about the same moment, in contrast to a more random distribution 
later on. To account for this phenomenon, we treated as binomial variable 
the chance of developing a score point, assuming a simultaneous start, a 
variable rate of progression between different sites, and equal spacing of 
the scores per site relative to the disease dose. The chance of p. of devel­
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Figure 7. Model for the uniform relationship between individual time inte­
grated CRP values (CRP AUC) and radiological progression (“disease 
dose” = k-CRP AUC). Curve a: relationship according to equation I: X 
damage = N-(l-e'k'CRPAUC). Curve b: adjustment of curve a for discontinu­
ous scoring (equation 2). Curve c: adjustment of curve b for synchronous 
scoring in the lower range of radiologic scores (equation 7). Curve c results 
from combining curve d and curve e. Curve d: adjusted relationship for 
erosions only. Curve e: adjusted relationship for narrowing only.
oping a score point i is proportional to the damage (1—e_k*CRP Auc) and 
inversely related to the proportion of existing score points (i/m):
p. = ( l -e 'k'CKPALJC)*m/i7 (3)
As the real starting point is unknown, we have to rely on relative val­
ues, using as a reference point the situation where (l_e'k‘CIiI,AUC) = i/m and 
where 50% of sites will have reached score point i (pj = 0,5), Thus, p. = 
i/nvm/i-y = 0.5, which means that y = 1/2.
All other values of ( I -e 'k'CRPAUC) can thus be expressed relative to i/m
as
i/m-( I -e'k‘CRPAuC) (4)
This formula can be transformed using the chance p( as expressed in equa­
tion 3 and substitution of y with 1/2
i/m-U~e'^GRPAUC) = i / m-( 1 - e ' k‘c RP AU c) - (m/2 i )■( 2 i /m) 
When (l~e'k’CRPAUCHm/2i) is replaced with according to equation 3, 
the resultant equation is
(l/2-pj)’(2i/m) or Apj*(2i/m) (5)
where Apj is the distance on the disease dose scale to the point i/m. 
Assuming a binomial distribution of p. the SD of pj will be 
V(PrO - Pj))/N and the SD of (1/2 pi)*(2i/m) will be
V{2Fp70^ Pi)ymN (6)
In this way for each disease dose the distance to the point where 50% of 
sites will have reached score point i can be expressed in the number of SD 
as:
((1 /2-p j H 2 i /m))/(V (Sl’p^T11^ ) / ® ) (7)
From the distance in SD (z) the percentage of n with score i can be esti­
mated using the table of probabilities for the standard Gaussian or normal 
distribution. Multiplying this percentage with n will yield the number of 
sites with score i. This procedure can be repeated for each value of i and the 
results summed to produce the overall curves for erosions and narrowing 
separately (because of the different m values for erosions and narrowing) 
and will result in curves d and e, respectively.
Summing these 2 curves yields curve c in Figure 1, representing the 
final theoretical model.
Calculations and statistics. Multi variate regression analysis was performed 
after log transformation of X scores, CRP levels, and k values. Patients 
were categorized according to sex, RF status, and HLA type. Spearman 
rank analysis was used for single correlations.
“True” k values were calculated with the use of curve c of Figure 1, in 
those patients who showed a rise in X scores during the total time period of
3 years. Their first positive X score was read from the curve to yield the 
"disease dose” at that moment, and the disease dose after 3 years was 
assessed using curve c and the X score after 3 years. The change in disease 
dose was divided by the concomitant change in CRP AUC to result in the 
individual true k values.
In those patients showing radiological progression during the first 3 
years, the k values were also calculated for the time intervals 0-6, 0-12, 
0-18, 0-24, and 0-30 months, provided that at least 2 positive scores were 
found within the respective period. For intervals during which the X score 
did not increase, the change was set at 0.5. For the comparison of predict­
ed and observed scores absolute differences were used for scores < 20 
points, whereas relati ve differences were used for scores > 20 points. Ratios 
between the estimated k values for the respective time intervals 0-t (kt)and 
true (3 years) k values were log transformed before further treatment. In 
addition, log transformation was performed of the ratios of predicted and 
observed scores for observed scores > 20 points. Agreement is given as the 
mean, its 95% confidence interval (Cl), and the 95% limits of agreement 
(mean difference ± 1.96 SD of differences) for absolute differences 
(observed scores < 20) and as their antilogs for the ratios17. The standard 
error (SE) of the estimation of k values and the prediction of scores is given 
as a percentage of the mean (eSD-l)*l00%.
Estimation of the k value from entry data was performed using the for­
mula describing the relative weight o f independently contributing prognos­
tic factors. A p value < 0.05 was considered statistically significant.
RESULTS
P atien ts  a n d  trea tm en ts . From the 149 patients with at least 
3 years followup (Table 1), a subgroup of 54 patients had 
completed 6 years followup at the time of analysis. The only 
significant difference between these 54 patients and the rest 
was their age, median 50 and 55 years, respectively (p < 
0.05). During the first 3 years, 133 patients were treated 
with DMARD, mainly hydroxychloroquine, intramuscular 
gold, and sulfasalazine, either as the only DMARD, or in 
succession. Ten patients were treated with methotrexate or 
azathioprine. Thirteen patients were taking additional low 
dose corticosteroids during some of the followup period. 
R a d io lo g ic  resu lts a n d  p ro g n o s tic  fa c to rs . Total radiologic 
scores (X scores) after 0.5, I, 2, and 3 years and the X scores 
after 6 years are shown in Table 2. Progression of radiolog­
ical damage was observed in 82, 117, 121, 123, 123, 123 
patients during time intervals of 0-6, 0-12, 0-18, 0-24, 
0-30, and 0-36 months, respectively. Multivariate regres­
sion analysis was performed using a selection of variables 
based on previous studies on prognostic factors in this 
patient group14,18. No data for HLA-DR subtypes were
Table 1. Patient characteristics at study entry (n = 149).
Age (yrs), median (range) 53 (16-77)
Sex f:m, no. of patients (%) 94:55 (63:37)
IgM RF positive (> 10 IU/ml), no. o f patients (%) 121 (81)
Initial CRP level (mg/1), median (range) 20 (0.1-260)
HLA-DR4, no. of patients (%) 90 (60)
HLA-DR2, no. of patients (%) 29 (16) 
Duration of complaints at study
entry (weeks), median (range) 26 (6-52)
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Table 2. Development of radiologie scores over 3 yrs (n = 149) and 6 years 
of followup (n = 54).
Followup
3 Year Followup (n = 149) 
Median Interquartile
6 Year Followup (n = 54) 
Median Interquartile
(yrs) Range Range
0 1 0-6 1 0-A
0.5 6 1-15 4.5 1-18
1 12 1-19 7.5 2-28
2 20 4-44 16.5 4-51
3 23 6-53 21 5-71
6 51 18-108
available. The result showed that progression of radiological 
damage over 3 years was significantly related (multiple R =
0.683) to the initial X score (p < 0.001), RF positivity (p <
0.001), initial CRP level (p < 0.001), absence of HLA-DR2 
(p < 0.002), and younger age (p < 0.03). There was no rela­
tionship to HLA-DR4 (p = 0.52) or sex (p = 0.77). However, 
when RF was omitted as an independent variable, HLA- 
DR4 appeared to contribute significantly.
Time in teg ra ted  C RP values and  rad io log ic  p ro g ress io n . 
Spearman rank correlation coefficients between CRP AUC 
values and radiologic progression over the first 3 years 
were, respectively, 0.656 (p < 0.001) for the whole group of 
149 patients and 0.651 (p < 0.001) for the subgroup of 54. 
For this subgroup, the correlation coefficient over 6 years 
was 0.666 (p < 0.001). In each individual, the relationship 
between S-X score and 5-CRP AUC approximated a straight 
line, indicating that the individual relationship was rather 
constant over time (Figure 2).
Calculated, ind iv idua l true k va lues. Individual k values 
were calculated as described in Materials and Methods. The 
individual k value represents the individual ratio between 
CRP production, as a variable of inflammatory activity, and 
the rate of progression of radiologic damage. The k value 
could be calculated in the 123 patients showing radiological 
progression during the 3 y eat' followup (k values cannot be 
calculated in patients without radiological damage). The 
geometric mean of the k  values was 18.9 X 10"6 1/mg 
CRP/week, with a range from 0.9 x 10' 6 to 401.6 x 10”61/mg 
CRP/week, showing the wide interindividual variance in 
this variable, yielding a coefficient of variance of 192%.
The k va lue a n d  rad io log ic  progression . After inclusion of 
the individually calculated k values, multivariate regression 
analysis identified highly significant correlation coefficients 
between progression in X score over 3 years and positive 
RF, initial CRP level, and k value (all p < 0.001, multiple R 
= 0.919). In contrast to the analysis for characteristics at 
entry without k values, initial X score (p = 0.20), absence of 
HLA-DR2 (p = 0.84), and age (p = 0.63) no longer correlat­
ed with the 3 year radiologic progression; HLA-DR4 (p =
0.60) and sex (p = 0,25) were still not related. The k value 
itself correlated (multiple R = 0.62) with RF positivity, 
absence of HLA-DR2, initial X score (all p < 0.001), and
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Figure 2, (a) Intraindividual relations between time integrated CRP values 
(CRP AUC) and radiological progression during 6 years of followup (N = 
54). (b) Enlargement of the lower left comer of (a).
younger age (p = 0.004). The equation describing the rela­
tive weight of independently contributing prognostic factors 
was equation A:
ln(k* 103) = -4.185-0.022*age + 1.089-RF-
(A)0.952-HLA-DR2 + 0.299-ln(Xo + 1)
where RF and HLA-DR2 were treated as categorical vari­
ables.
E stim ation  o f  k  va lue  in very  ea rly  d ise a se  and. va lid a tio n  o f  
the m o d e l The k value used in the regression analysis was
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derived from the results of the full 3 year follow up. In clin­
ical practice, however, an accurate estimate of k after a
calculated. In patients with X score > 20 points relative val­
ues were compared, whereas absolute values were used for
shorter time interval would be useful to predict disease out- the comparison in patients with an X scoie of ^ 20 points.
come reflected by radiologic score. To be regarded as clini­
cally useful a model should enable a reliable estimate of the 
k value as early as 6-12 months after diagnosis.
To assess its predictive accuracy, k values were estimat­
ed at different time intervals (0-6, 0-12, 0-18, 0-24, 0-30 
months) and expressed as a percentage of the true k value 
derived from the full 36 month period. The results are given 
in Table 3. The k values are stable in time, being slightly 
overestimated in the first 24 months compared to the true k 
value. The agreement between estimated k value and true k 
value increases with the length of the interval,
A ccu ra cy  o f  the k  value and  its pred ictive use. As described 
above, k values over 3 year data could be calculated in those 
patients showing X progression during this period (N = 
123). In 82/123 patients with an initial X score > 0, k values 
could be calculated after 6 months, and in 117/123 patients 
with a 6 month X score > 0, k values after 1 year could be
At first, X scores at 3 years were predicted using k val­
ues obtained from data at entry using equation A and the 
actual CRP levels during the 3 year followup. The predicted 
results were compared with the X scores actually observed 
after 3 years (Figure 3a and Table 4). Of the 82 patients with 
an initial X score > 0 ,  19 patients had an observed score 
below 21 after 3 year followup. In these patients, the pre­
dicted scores were not statistically different from the 
observed scores, though the 95% limits of agreement ranged 
from -39 to +25, In the 63 patients with an observed X score 
of > 20 points after 3 year followup, the predicted scores 
were statistically different from the observed scores (85%, 
Table 4) with a SE for predicted scores of 56%.
Second, X scores at 3 years were predicted using k val­
ues obtained with data from the first half year using curve b  
and the actual CRP levels during the 3 year followup in the 
same 82 patients. For observed scores of ^  20 points, the
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Figure 3. Relation between predicted X scoi e find observed X score after 3 years in patients with X progression during 3 yeitr followup mid un initial X scoro 
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Table 3. Agreement of k values estimated over different time periods and 
expressed as a percentage of the true k values, derived from full 36 month 
data.
Interval
(mo)
N k Value, % of 
3 Yrs Value
95% Cl SE, % 
of Mean
At entry 123 74.5 62.1-89.3 179
0-6 82 115.5 99.3-134.3 101
0-12 117 113.6 103.8-124.2 64
0-18 121 113.1 105.1-121.8 51
0-24 123 107.1 99.9-115.0 49
0-30 123 101.7 994-103.9 13
0-36 123 100.0
N: number of patients with radiological progression over a period of 3 
years who had at least 2 X scores > 0 within the respective time intervals.
predicted scores were not statistically different from the 
observed scores, though the 95% limits of agreement ranged 
from -15 to +12. For observed scores of > 20 points after 3 
years, the predicted scores were only 87% of the observed 
ones, with a SE of 88% (Figure 3b and Table 4).
Third, X scores at 3 years were predicted using k values 
obtained with data from the first half year using curve c and 
the actual CRP levels during the 3 year followup in the same 
82 patients. For observed scores of < 20 points the predict­
ed scores were not statistically different from the observed 
ones, with 95% limits of agreement from -14 to +19. For 
observed scores of > 20 points the predicted scores were not 
statistically different (104%) from the observed ones, with a 
SE of 72% (Table 4 and Figure 3c).
Fourth, X scores after 3 years were predicted using the k 
value calculated from the 1 year data using curve c and the 
actual CRP values over 3 years. The k value could be esti­
mated in the 117 patients with an X score > 0 at 6 months. 
In 34 of them the observed score at 3 years was < 20 points. 
The predicted scores were statistically slightly above the 
observed ones, with 95% limits of agreement ranging from 
-10 to +13. In the other 83 patients with an observed score 
> 20, the predicted scores were not statistically different 
from the observed ones (109%), with a SE of 57% (Table 4 
and Figure 3d).
Finally, the 1 year k values derived from curve c and
actual CRP values over 6 years were used to predict the X 
score at 6 years in the subgroup of 54 patients. As only 4 
patients had X scores of < 20 points, separate calculation of 
the lower range using absolute values was omitted. In the 43 
patients with X score > 0 at 6 months, the predicted scores 
were 97% of the observed ones (95% Cl from 85 to 112%,  
95% limits of agreement from 44 to 215%) with a SE of 
51%.
The influence of specific drug treatments on the k value 
could not reliably be evaluated, because insufficient num­
bers of patients were treated with one specific DMARD 
throughout the study period (according to the followup pro­
tocol DMARD could be changed as clinically indicated, 
independent of the radiographic intervals)* We evaluated the 
data of those patients who were treated with a specific 
DMARD during at least 9 months of the first year of the 
study. If this main drug was added to the independent vari­
ables in the analysis, no significant differences in k values 
of the first year were found for hydroxychloroquine, sul­
fasalazine, or gold.
Use o f  E S R  in s te a d  o f  CRP. Use of ESR instead of CRP as 
the indicator of acute phase response yielded essentially the 
same results in this model.
DISCUSSION
Our study evaluates the monitoring of disease activity aimed 
at prediction of radiologic outcome in early RA for individ­
ual patients. The results of radiologic damage of our patients 
are in agreement with the work of others, indicating that a 
majority of patients with RA will develop radiologic joint 
damage of hands and feet within the first year of the dis­
ease1’2. Inclusion of the foot joints in the assessment of early 
joint damage is important because early abnormalities may 
occur in the absence of radiological damage in hands or 
wrists19,20. This early, largely irreversible joint damage is a 
major argument for starting potentially effective drug treat­
ment soon after presentation21. The factors that predicted 
radiologic progression in our patients were those commonly 
reported in the literature7’22“24, including RF, HLA-DR4, 
absence of HLA-DR2, and high disease activity (measured
Table 4. Agreement of predicted and observed X scores over 3 years; comparison of different k values.
k Value at Entry, 
Curve c
k Value at 0.5 yrs, 
Curve b
k Value at 0.5 yrs, 
Curve c
k Value at 1 yr, 
Curve c
Values > 20 N = 63 N = 63 N = 63
00II2
Mean at 3 yrs {%) 85 87 104 109
95% Cl of mean 76-95 75-102 89-122 99-121
95% LOA 35-203 25-300 31-358 46-263
SE (% mean) 56 88 72 57
Values ^  20 N =  19
<3\II
z
N = 19 N = 34
Mean at 3 yrs (abs) 6 -2 2 2
95% Cl of mean -4-17 -5 -2 -2 -6 0-4
95% LOA -39-52 -15-12 -1 4 -1 9 -10-13
LOA: limits of agreement.
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by CRP levels), and they contributed independently to out­
come with an explained variance of 46%. When analyzed 
together in a multivariate regression analysis, RF and 
absence of HLA-DR2 appeared to have a predictive value 
higher than HLA-DR4, indicating RF may act as a surrogate 
marker for HLA-DR4. Reports concerning the contribution 
of age are contradictory25’26. Although prognostic factors 
assist early identification of patients at risk of progressive 
disease, and radiologic damage can be predicted better if 
data concerning the course of the disease during the first 6 
months are included18, the predictive value for individual 
patients remains limited.
The acute phase response is a suitable marker for 
longterm objective monitoring of disease activity, and it has 
been shown to be related to the progression of radiologic 
damage. The low basal levels, rapid increase, and short half- 
life of CRP compared with fibrinogen, which is mainly 
responsible for the ESR, are arguments in favor of CRP 
measurement. Furthermore, the only determinant of circu­
lating CRP levels is the synthesis rate of CRP, so that the 
time integrated CRP (CRP AUC) is a proper measure of 
cumulative CRP production27.
The significant overall correlation between time integrat­
ed CRP values and radiologic progression, previously 
reported in these patients over 3 year followup12, was con­
firmed here for followup of 6 years in a subgroup of 54 
patients and is in agreement with the study of Hassell, et 
a/28. However, the wide interindividual variation of the rela­
tionship between CRP levels and radiologic progression 
limits the use of single CRP measurements for the prediction 
of outcome in individual patients. Knowledge at an early 
stage of the disease of the specific relationship between 
CRP levels and radiologic progression in each patient would 
enable the clinician to identify those at risk, and to deter­
mine the range of CRP levels within which joint damage 
would be limited.
We have therefore developed and validated a model to 
describe the individual relationship between CRP levels and 
radiologic progression, which accounts for the discontinuity 
of the radiologic damage scoring system and the problem of 
synchronous scoring as radiologic damage begins.
The k value, representing the individual relationship 
between CRP levels and radiologic progression, indeed 
showed wide interindividual variation, with a coefficient of 
variance of 192%. Therefore, it is important to estimate the 
k value as soon as possible to adjust the estimation of the 
prognosis of an individual patient.
Estimates of individual k values from entry data can be 
made in early disease, though slight over estimation tends to 
occur during the phase of declining CRP levels, because 
radiologic score and CRP levels are slightly out of phase, as 
we have shown12. In our data there appears to be substantial 
overestimation up to 2 years when using the k value from 
entry characteristics. The SE of the estimated k value
improves from 179% when using entry data, to 101 and 64% 
using 6 month data and 1 year data, respectively (Table 3). 
It is essential to use a model that takes into account syn­
chronous scoring in early disease (curve c), as the predicted 
score will be underestimated using a model that includes 
only the discontinuity of scoring (curve b). From a clinical 
point of view, underestimation is more difficult to correct 
with regai'd to treatment than overestimation. The SE of the 
predicted score at 3 years using 1 year data amounts to 57%. 
Yet the error in the predicted score is much lower than the 
observed interindividual variation of 192% of the relation­
ship between CRP production and radiologic progression, 
which one would have to deal with if the k value is not used 
for prediction of radiologic progression. The SE of the pre­
dicted scores at 3 and 6 years, using 1 year data for the esti­
mation of the k value, are similar (57 and 51%, respective­
ly). This indicates that longterm prediction with acceptable 
accuracy is possible.
Calculations of k values and prediction of radiological 
progression were performed irrespective of the specific drug 
treatments. Analysis of the influence of DMARD on k val­
ues yielded no drug specific differences for hydroxychloro­
quine, sulfasalazine, or gold. These findings support the 
assumption that any treatment that affects radiological pro­
gression also affects CRP and ESR proportionally.
The present model can thus be used as the basis of a deci­
sion support system in which monitoring of CRP and regu­
lar radiologic scoring during followup enable the k value of 
individual patients to be determined with progressively 
greater precision. This in turn can be used to predict radio­
logic progression with increasing accuracy, and, important­
ly, to determine levels of CRP below which further radio­
logic damage should not occur. The model is unsuitable for 
patients with no radiologic damage after 6 or 12 months. 
However, such cases usually have a good prognosis, and in 
the present series only 4 of 21 individuals with no damage 
at 6-12 months developed lesions after 3 years.
For routine clinical use the model has been incorporated 
into a software program in which it is combined with the 
prognostic factors of each patient, and consecutive CRP lev­
els during followup are translated into a radiologic progno­
sis, assuming that CRP production will remain unchanged. 
This prognosis is then updated with each new CRP mea­
surement and with the revised k value obtained after each 
set of radiographs has provided the current X score. It 
should be emphasized that this interpretation of CRP values 
with regard to radiological progression in the individual 
patient can support, but not replace, clinical decision mak­
ing. A decision support system is not a “brain prosthesis,’1 
but rather an instrument bringing together the knowledge 
and the expertise needed to solve complex clinical prob­
lems. Although the model has been designed for use with 
CRP measurements, its performance using the ESR as an 
indicator of the acute phase response was very similar. This
26 The Journal o f Rheumatology 1997; 24:1
is not surprising, as the ESR is essentially a time integrated 
variable reflecting disease activity during the preceding sev­
eral weeks. Further detailed analysis, with particular refer­
ence to lower range values, will be required to establish 
whether CRP, ESR, or possibly the other sensitive acute 
phase reactant, serum amyloid A protein, is the best indica­
tor of the acute phase response in this system. Regarding the 
good correlation between radiologic progression and 
swollen joint counts29, analysis of the performance of clini­
cal variables may be warranted. Further detailed analysis 
will be needed to establish the mechanism by which certain 
factors influence the k values. Meanwhile, the performance 
of the present CRP model in monitoring the effects of drug 
treatment is being assessed in a prospective study in patients 
with early RA.
ACKNOWLEDGMENT
We thank W, Lolkema and J. Westra for the clinical and laboratory mea­
surements and P. Royston for statistical counselling.
REFERENCES
1. Brook A, Corbett M: Radiographic changes in early rheumatoid 
disease. Ann Rheum Dis 1977;36:71-3.
2. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T: Evidence of 
significant radiographic damage in rheumatoid arthritis within the 
first 2 years of disease. J Rheumatol /959/ 16:585-91.
3. Corbett M, Dalton S, Young A, Silman A, Shipley M: Factors 
predicting death, survival and functional outcome in a prospective 
study of early rheumatoid disease over fifteen years. Br J Rheumatol 
7995/32:717-23.
4. Scott DL, Coulton BL, Popert AJ: Long term progression of joint 
damage in rheumatoid arthritis. Ann Rheum Dis 7956/45:373-8,
5. Fries JF, Bloch DA, Sharp JT, et at: Assessment of radiologic 
progression in rheumatoid arthritis. A randomized, controlled trial. 
Arthritis Rheum 1986;29:1-9.
6. Sharp JT: Radiologic assessment as an outcome measure in 
rheumatoid arthritis, Arthritis Rheum 1989;32:221-9.
7. Van der Heijde DMFM, van Riel PLCM, van Rijswijk MH, van de 
Putte LB A: Influence of prognostic factors on the final outcome in 
rheumatoid arthritis: A review of the literature. Semin Arthritis 
Rheum 1988; 17:284-92.
8. Van Rijswijk MH, Ruinen L, Marrink J, De Blicourt JJ: Some 
aspects of SAA and CRP measurements in patients with rheumatoid 
arthritis. In: Feltkamp TEW, van der Korst JK, eds. Disease 
Evaluation and Patient Assessment in Rheumatoid Arthritis. Alphen 
a/d Rijn, Brussels: Staphleu’s Scientific, 1979:145—50.
9. Mallya RK, De Beer FC, Berry H, Hamilton EDW, Mace BEW, 
Pepys MB: Correlation of clinical parameters of disease activity in 
rheumatoid arthritis with serum concentrations of C-reactive protein 
and erythrocyte sedimentation rate. J Rheumatol 1982;9:224-8.
10. Amos RS, Constable TJ, Crockson RA, Crockson AP, McConkey B: 
Rheumatoid arthritis: Relation of serum C-reactive protein and 
erythrocyte sedimentation rates to radio-graphic changes. BMJ
7977/1:195-7.
11. Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shadforth MF: 
Rheumatoid arthritis: Treatment which controls the C-reactive 
protein and erythrocyte sedimentation rate reduces radiological 
progression. Br J Rheumatol 1986;25:44-9.
12. Van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM, el ah 
The acute-phase response in relation to radiographic progression in 
early rheumatoid arthritis: A prospective study during the first three
years of the disease. Br J Rheumatol 799J/(suppl 3)32:9-13.
13. Van Leeuwen MA, van Rijswijk MH, Marrink J, Westra J, De Jong 
HJ: CRP measurements in rheumatic disorders. Protides o f the 
Biological Fluids 7956/34:315-8,
14. Van Leeuwen MA, Westra J, van Riel PLCM, Limburg PC, van 
Rijswijk MH: IgM, IgA, and IgG rheumatoid factors in early 
rheumatoid arthritis. Predictive of radiological progression? ScandJ  
Rheumatol 7995/24:146-53.
15. Sharp JT, Young DY, Bluhm GB, et al: How many joints in the 
hands and wrists should be included in a score of radiologic 
abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 
/955/28:1326-35.
16. Van der Heijde DMFM, van Riel PLCM, Nuver-Zwart IH, Gribnau 
FWJ, van de Putte LB A: Effects of hydroxychloroquine and 
sulphasalazine on progression of joint damage in rheumatoid 
arthritis. Lancet 7959/1:1036—8.
17. Bland JM, Altman DG: Statistical methods for assessing agreement 
between two methods of clinical measurement. Lancet
795(5/307-10.
18. Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van’t 
Hof MA, van Rijswijk MH, van de Putte LBA: Prognostic factors 
for radiographic damage and physical disability in early rheumatoid 
arthritis. A prospective follow-up study of 147 patients. Br J  
Rheumatol 7992/31:519-25.
19. Paimela L: The radiographic criterion in the 1987 revised criteria for 
rheumatoid arthritis. Re-assessment in a prospective study of early 
disease. Arthritis Rheum 7992/35:255-8.
20. Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, et al: 
Biannual radiographic assessments of hands and feet in a three-year 
prospective follow-up of patients with early rheumatoid arthritis. 
Arthritis Rheum 1992;35:26-34.
2J. Donelly S, Scott DL, Emery P: The long-term outcome and 
justification for early treatment. Bailliere's Clin Rheumatol
7992/6:251-60.
22. Young A, Corbett M, Winfield J, et al: A prognostic index for 
erosive changes in the hands, feet, and cervical spines in early 
rheumatoid arthritis. Br J  Rheumatol 7955/27:94-101.
23. Van Zeben D, Hazes JM, Zwinderman AH, et al: Association of 
HLA-DR4 with a more progressive disease course in patients with 
rheumatoid arthritis. Results of a followup study. Arthritis Rheum 
7997/34:822-30.
24. Young A, Jaraquemada D, Awad J, et al: Association of HLA- 
DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective 
study of patients with rheumatoid arthritis. Arthritis Rheum 
7954/27:20-5,
25. Van der Heijde DMFM, van Riel PLCM, van Leeuwen MA, van’t 
Hof MA, van Rijswijk MH, van de Putte LBA: Older versus 
younger onset rheumatoid arthritis: Results at onset and after 2 years 
of a prospective follow-up study of early rheumatoid arthritis.
J Rheumatol 7997/18:1285-9.
26. Van Schaardenburg DJ, Hazes JMW, De Boer A, Zwinderman AH, 
Meijers KAE, Breedveld FC: Outcome of rheumatoid arthritis in 
relation to age and rheumatoid factor at diagnosis. J Rheumatol 
7995/20:45-52.
27. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic 
studies of radioiodinated human C-reactive protein in health and 
disease. J Clin Invest J993;9\: 1351-7.
28. Hassell AB, Davis MJ, Fowler PD, et al: The relationship between 
serial measures of disease activity and outcome in rheumatoid 
arthritis. Q J  Med 7995/86:601-7.
29. Van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, et a I: 
Interrelationship of outcome measures and process variables in early 
rheumatoid arthritis. A comparison of radiological damage, physical 
disability, joint counts, and acute phase reactants. J  Rheumatol
1994;2\ :425-9.
van Leeuwen, et al: Decision support in RA 27
